FDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is MTFB

Today's Daily Dose brings you news about Biohaven's collaboration with Alzheimer's Disease Cooperative Study; CHMP positive opinion on GlaxoSmithKline's Trelegy Ellipta and TESARO's ZEJULA; Orphan Drug designated Motif's investigational drug candidate, Iclaprim, and FDA approval of Neos' third extended release product for the treatment of ADHD.

from RTT - Biotech http://ift.tt/2wAd7w8
via IFTTT